Beta DrugsNSE:BETA -3.13%82 EBITDA Margin % is 21.89% as of Mar. 2026, which is 5% above its 10-year median of 20.90. GuruFocus rates NSE:BETA with a GF Score™ of 82/100 and a GF Value™ of ₹1,960.95 (Fairly Valued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Beta Drugs ranks better than 72.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Beta Drugs's EBITDA for the
three
months ended in Mar. 2026 was ₹206 Mil. Beta Drugs's Revenue for the
three
months ended in Mar. 2026 was ₹940 Mil. Therefore, Beta Drugs's EBITDA margin for the quarter that ended in Mar. 2026 was 21.89%.
Beta Drugs (NSE:BETA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Beta Drugs EBITDA Margin % Related Terms
Beta Drugs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Beta Drugs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Beta Drugs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a EBITDA Margin % of 21.89% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beta Drugs and its competitors. This is near median its historical median of 20.90. Over the past decade, Beta Drugs' EBITDA Margin % has ranged from 17.46 to 23.67. According to the industry distribution chart, Beta Drugs ranks #258 out of 955 companies in the Drug Manufacturers industry, placing it in the top 27%.
Is Beta Drugs' EBITDA Margin % too high?
Beta Drugs' current EBITDA Margin % of 21.89% is near median its 10-year median of 20.90. Over the past 10 years, this metric has ranged from a low of 17.46 to a high of 23.67. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Beta Drugs' value of 21.89% is 76% above this industry median. Based on the distribution chart, Beta Drugs ranks #258 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #258 out of 955 companies for EBITDA Margin %. This puts Beta Drugs in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Beta Drugs' value of 21.89% is 76% above this benchmark. Historically, Beta Drugs' own EBITDA Margin % has ranged from 17.46 to 23.67 over the past decade. While the company's 10-year median is 20.90 vs. the industry median of 12.44, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current EBITDA Margin % of 21.89% is 76% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current EBITDA Margin % is 21.89%, which is near median its own 10-year median of 20.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,960.95, compared to a current price of ₹2,096.60 — trading 6.9% above its estimated fair value. The current EBITDA Margin % is 21.89%, which is near median its 10-year median of 20.90 and 76% above the Drug Manufacturers industry median of 12.44. Beta Drugs' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current EBITDA Margin % is 21.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,096.60 is trading 6.9% above its estimated GF Value™ of ₹1,960.95.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
EBITDA Margin %: 21.89% (near median its 10-year median of 20.90)
GF Value™: ₹1,960.95 vs. price of ₹2,096.60 (6.9% above fair value)
Industry Position: 76% above the Drug Manufacturers median (#258 of 955)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score
Get the complete analysis for NSE:BETA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
